Abs of the IgG isotype mediate effector functions like Ab-dependent cellular cytotoxicity and Ab-dependent cellular phagocytosis by Fc interactions with FcγRs and complement-dependent cytotoxicity upon IgG-Fc binding to C1q. In this study, we describe the crucial role of the highly conserved dual glycines at position 236-237 in the lower hinge region of human IgG, including the lack of one glycine as found in IgG2. We found several permutations in this region that either silence or largely abrogate FcγR binding and downstream FcγR effector functions, as demonstrated by surface plasmon resonance, Ab-dependent cellular phagocytosis, and Ab-dependent cellular cytotoxicity assays. Although the binding regions of FcγRs and C1q on the IgG-Fc largely overlap, IgG1 with a deletion of G236 only silences FcγR-mediated effector functions without affecting C1q-binding or activation. Several mutations resulted in only residual FcγRI binding with differing affinities that are either complement competent or silenced. Interestingly, we also found that IgG2, naturally only binding FcγRIIa, gains binding to FcγRI and FcγRIIIa after insertion of G236, highlighting the crucial importance of G236 in IgG for FcγR interaction. These mutants may become invaluable tools for FcγR-related research as well as for therapeutic purposes in which only complement-mediated functions are required without the involvement of FcγR.

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.2000961DOI Listing

Publication Analysis

Top Keywords

ab-dependent cellular
16
effector functions
12
lower hinge
8
hinge region
8
region human
8
cellular cytotoxicity
8
cellular phagocytosis
8
binding
6
fcγr
5
glycine 236
4

Similar Publications

NK cells are specialized immune effector cells crucial for triggering immune responses against aberrant cells. Although recent advancements have concentrated on creating or releasing T-cell responses specific to tumor Ags, the clinical advantages of this approach have been limited to certain groups of patients and tumor types. This emphasizes the need for alternative strategies.

View Article and Find Full Text PDF

A Novel Engineering Cell Therapy Platform Mimicking the Immune Thrombocytopenia-Derived Platelets to Inhibit Cytokine Storm in Hemophagocytic Lymphohistiocytosis.

Adv Sci (Weinh)

December 2024

Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.

Article Synopsis
  • Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory condition with no specific treatments, caused by abnormal activation of macrophages.
  • Researchers have developed a new targeted therapy called anti-CD41-PLT-VP16, which combines engineered platelets and a drug (VP16) that induces macrophage death, showing effective results in both lab and live models.
  • Early clinical trials indicate that this innovative therapy significantly improves patient outcomes, tripling the response rate compared to standard treatments for HLH.
View Article and Find Full Text PDF

Infection before primary vaccination (herein termed "hybrid immunity") engenders robust humoral immunity and broad Ab-dependent cell-mediated cytotoxicity (ADCC) across SARS-CoV-2 variants. We measured and compared plasma IgG and IgA against Wuhan-Hu-1 and Omicron (B.1.

View Article and Find Full Text PDF

Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption.

Cell Rep

June 2024

US Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA. Electronic address:

Article Synopsis
  • - The study examined the effects of a heterologous Ad26/MVA vaccine on immune responses in people living with HIV-1 who interrupted their antiretroviral treatment.
  • - It was found that while the vaccine primarily produced binding antibodies related to the vaccine strain, these did not correlate with the time it took for the virus to rebound after treatment interruption.
  • - Individuals who experienced delayed viral rebound had significantly higher levels of antibodies that promote phagocytosis (ADCP), suggesting that vaccines generating cross-reactive immune responses could help in controlling the virus after treatment stops.
View Article and Find Full Text PDF

Human IgA Abs engage neutrophils for cancer immunotherapy more effectively than IgG Abs. Previous studies demonstrated that engineering approaches improved biochemical and functional properties. In this study, we report a novel, to our knowledge, IgA2 Ab against the epidermal growth factor receptor generated by protein engineering and polymerization.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!